"Carcinoma in Situ" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
| Descriptor ID |
D002278
|
| MeSH Number(s) |
C04.557.470.200.240
|
| Concept/Terms |
Carcinoma in Situ- Carcinoma in Situ
- Carcinoma, Preinvasive
- Preinvasive Carcinoma
- Carcinoma, Intraepithelial
- Intraepithelial Carcinoma
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma in Situ".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma in Situ".
This graph shows the total number of publications written about "Carcinoma in Situ" by people in this website by year, and whether "Carcinoma in Situ" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 3 | 4 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 1 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 5 | 0 | 5 |
| 2013 | 3 | 0 | 3 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 1 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma in Situ" by people in Profiles.
-
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
-
Detection of Human Papillomavirus in Squamous Lesions of the Conjunctiva Using RNA and DNA In-Situ Hybridization. Int J Mol Sci. 2022 Jun 29; 23(13).
-
Hysterectomy with a general gynecologist vs gynecologic-oncologist in the setting of endometrial intraepithelial neoplasia: a cost-effectiveness analysis. Am J Obstet Gynecol. 2022 10; 227(4):609.e1-609.e8.
-
Gallbladder Cancer: A Single-Institution 10-Year Experience-Analysis of Adenocarcinoma Subtypes and Tumors Arising from Intracholecystic Papillary Neoplasms. Ann Surg Oncol. 2022 Aug; 29(8):5167-5175.
-
Vulvar Intraepithelial Neoplasia: A Review of the Disease and Current Management. Obstet Gynecol Surv. 2021 Jan; 76(1):55-62.
-
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
-
Targeting cholecystokinin-2 receptor for pancreatic cancer chemoprevention. Mol Carcinog. 2019 10; 58(10):1908-1918.
-
Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. World J Urol. 2019 Jan; 37(1):165-172.
-
Treatment of Head and Neck Melanoma In Situ With Staged Contoured Marginal Excisions. Ann Plast Surg. 2017 Jun; 78(6):663-667.
-
Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+ mice. Immunology. 2017 09; 152(1):36-51.